Autologous myeloid dendritic cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Autologous myeloid dendritic cells, covering 2025-11-21 to 2025-11-21. Get the full timeline:
Most recent: Clinical Trial Update: A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma. [Phase 1, Phase 2]